Table 1.
Comparison of neutralization potencies of the same nAbs obtained in plants and mammalian cells.
| nAb | Neutralization potency | |
|---|---|---|
| Plant-produced nAb | Mammalian cell-produced nAb | |
| 675 | IC100: 214.3 ng/mL (this study) | IC50: 19.5 ng/mL (Wang et al., 2021) IC90: 111.6 ng/mL (Wang et al., 2021) |
| J08-MUT | IC100: 16.8 ng/mL (this study) | IC100: 7.2 ng/mL (this study) |
| CA1 | IC50: 1390 ng/mL (Jugler et al., 2022) | IC50: 4981 ng/mL (Shi et al., 2020) |
| CB6 | IC50: 139 ng/mL (Jugler et al., 2022) | IC50: 835 ng/mL (Shi et al., 2020) |
| B38 | NT40 at 5450 ng/mL (Shanmugaraj et al., 2020) | IC50: 177 ng /mL (Wu et al., 2020) |
| H4 | NT 640 at 492 ng/mL (Shanmugaraj et al., 2020) | IC50: 896 ng/mL (Wu et al., 2020) |
| H4-IgG3 | IC100: 1000 ng/mL (Kallolimath et al., 2021) | IC50: 896 ng/mL (Wu et al., 2020) |
In these studies, potencies were calculated using cytopathic effect (CPE)-based neutralization assays on Vero E6 cells and were expressed as inhibitory concentration (IC) except for the work by Shanmugaraj et al. in which neutralization titer (NT) was reported. The IC is defined as the antibody concentration at which the viral replication has been reduced by 50% (IC50), 90% (IC90), or 100% (IC100).